Opinion|Videos|June 2, 2025
Outcomes in Black patients receiving darolutamide plus ADT for mHSPC
Author(s)Quoc-Dien Trinh, MD, MPH
Emerging data on mHSPC shows promising trends in overall survival, highlighting the impact of care access and competing risks.
Advertisement
Episodes in this series
Overall Survival Considerations
Key Themes:
- ARANOTE’s overall survival data are still maturing.
- ARASENS data show a promising trend for survival benefit.
- Competing risks and care access issues complicate survival analysis.
- Treatment completion challenges may impact long-term outcomes.
Key Points for Physicians:
- Although definitive overall survival data are pending, trends appear promising.
- Consider social determinants and access issues that may impact long-term outcomes.
- Address potential barriers to treatment completion.
- Monitor for mature survival data as they become available.
Notable Insights: The complexity of survival analysis highlights the importance of considering factors beyond drug efficacy, particularly access to care and treatment completion, which may disproportionately affect Black patients.
Clinical Significance: Early survival trends appear promising but require longer follow-up and consideration of the broader context of care delivery and social determinants that influence outcomes.
Advertisement
Related to this article
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
Engy Habashy, MD, on the role of androgens in GSM management
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5